Agilent Technologies Inc. Enters Partnership with Ubix Therapeutics to Advance Cancer Research in South Korea

Reuters

14 May

Agilent Technologies Inc. Enters Partnership with Ubix <a href="https://laohu8.com/S/LENZ">Therapeutics</a> to Advance Cancer Research in South Korea

**Agilent Technologies Inc. Partners with Ubix Therapeutics to Accelerate Cancer Research in South Korea** SEOUL, South Korea - Agilent Technologies Inc. $(A)$ has announced a new partnership with Ubix Therapeutics to advance targeted cancer therapy research and development in South Korea. Over the next five years, this collaboration will focus on developing targeted protein degradation $(TPD.AU)$ and antibody-drug conjugate $(ADC)$ therapies. The partnership combines Ubix's Degraducer® anti-cancer drugs platform with Agilent's cutting-edge research and technology capabilities. This initiative aims to enhance precision oncology, with the global TPD market projected to reach USD 4.37 billion by 2034. This collaboration underscores Agilent's commitment to transformative cancer therapy and South Korea's biomedical advancement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agilent Technologies Inc. published the original content used to generate this news brief on May 14, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2535026035"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535026035\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2535026035?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-14 06:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535026035","market":"nz","top_or_hot":-1,"title":"Agilent Technologies Inc. Enters Partnership with Ubix Therapeutics to Advance Cancer Research in South Korea","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Agilent Technologies Inc. Enters Partnership with Ubix <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to Advance Cancer Research in South Korea\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        **Agilent Technologies Inc. Partners with Ubix Therapeutics to Accelerate Cancer Research in South Korea** SEOUL, South Korea - Agilent Technologies Inc. <a href=\"https://laohu8.com/S/A\">$(A)$</a> has announced a new partnership with Ubix Therapeutics to advance targeted cancer therapy research and development in South Korea. Over the next five years, this collaboration will focus on developing targeted protein degradation <a href=\"https://laohu8.com/S/TPD.AU\">$(TPD.AU)$</a> and antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a> therapies. The partnership combines Ubix's Degraducer® anti-cancer drugs platform with Agilent's cutting-edge research and technology capabilities. This initiative aims to enhance precision oncology, with the global TPD market projected to reach USD 4.37 billion by 2034. This collaboration underscores Agilent's commitment to transformative cancer therapy and South Korea's biomedical advancement.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agilent Technologies Inc. published the original content used to generate this news brief on May 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Agilent Technologies Inc. Enters Partnership with Ubix Therapeutics to Advance Cancer Research in South Korea</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAgilent Technologies Inc. Enters Partnership with Ubix Therapeutics to Advance Cancer Research in South Korea\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-14 06:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Agilent Technologies Inc. Enters Partnership with Ubix <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to Advance Cancer Research in South Korea\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        **Agilent Technologies Inc. Partners with Ubix Therapeutics to Accelerate Cancer Research in South Korea** SEOUL, South Korea - Agilent Technologies Inc. <a href=\"https://laohu8.com/S/A\">$(A)$</a> has announced a new partnership with Ubix Therapeutics to advance targeted cancer therapy research and development in South Korea. Over the next five years, this collaboration will focus on developing targeted protein degradation <a href=\"https://laohu8.com/S/TPD.AU\">$(TPD.AU)$</a> and antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a> therapies. The partnership combines Ubix's Degraducer® anti-cancer drugs platform with Agilent's cutting-edge research and technology capabilities. This initiative aims to enhance precision oncology, with the global TPD market projected to reach USD 4.37 billion by 2034. This collaboration underscores Agilent's commitment to transformative cancer therapy and South Korea's biomedical advancement.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agilent Technologies Inc. published the original content used to generate this news brief on May 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nNDL360lQF:1","article_id":"2535026035","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535026035","pubTimestamp":1747175153,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"**Agilent Technologies Inc. Partners with Ubix Therapeutics to Accelerate Cancer Research in South Korea** SEOUL, South Korea - Agilent Technologies Inc.  has announced a new partnership with Ubix Therapeutics to advance targeted cancer therapy research and development in South Korea. Over the next five years, this collaboration will focus on developing targeted protein degradation  and antibody-drug conjugate  therapies. The partnership combines Ubix's Degraducer anti-cancer drugs platform with Agilent's cutting-edge research and technology capabilities. This initiative aims to enhance precision oncology, with the global TPD market projected to reach USD 4.37 billion by 2034. This collaboration underscores Agilent's commitment to transformative cancer therapy and South Korea's biomedical advancement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated c","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"安捷伦科技公司与Ubix Therapeutics合作推进韩国癌症研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"A":0.9},"content_text":"Agilent Technologies Inc. Enters Partnership with Ubix Therapeutics to Advance Cancer Research in South Korea\n    \n\n        **Agilent Technologies Inc. Partners with Ubix Therapeutics to Accelerate Cancer Research in South Korea** SEOUL, South Korea - Agilent Technologies Inc. $(A)$ has announced a new partnership with Ubix Therapeutics to advance targeted cancer therapy research and development in South Korea. Over the next five years, this collaboration will focus on developing targeted protein degradation $(TPD.AU)$ and antibody-drug conjugate $(ADC)$ therapies. The partnership combines Ubix's Degraducer® anti-cancer drugs platform with Agilent's cutting-edge research and technology capabilities. This initiative aims to enhance precision oncology, with the global TPD market projected to reach USD 4.37 billion by 2034. This collaboration underscores Agilent's commitment to transformative cancer therapy and South Korea's biomedical advancement.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agilent Technologies Inc. published the original content used to generate this news brief on May 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}